Range Impact, Inc. engages in unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. It operates through Pharmaceutical Operations and Clinical Operations segments. The Clinical Operations segment focuses on treating patients suffering from addiction and dependency. The Pharmaceutical Operations segment engages in research and development primarily related to the Company’s cannabinoid pharmaceuticals. The company was founded by Avtar S. Dhillon and Robert T. Brooke on June 29, 2007 and is headquartered in Cleveland, OH.